- Home
- FUFUW vs CMMB Comparison
FUFUW vs CMMB Comparison
Compare FUFUW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUFUW
- CMMB
- Stock Information
- Founded
- FUFUW N/A
- CMMB 2004
- Country
- FUFUW Singapore
- CMMB Israel
- Employees
- FUFUW N/A
- CMMB N/A
- Industry
- FUFUW
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FUFUW
- CMMB Health Care
- Exchange
- FUFUW Nasdaq
- CMMB Nasdaq
- Market Cap
- FUFUW N/A
- CMMB 23.6M
- IPO Year
- FUFUW N/A
- CMMB N/A
- Fundamental
- Price
- FUFUW $0.43
- CMMB $1.39
- Analyst Decision
- FUFUW
- CMMB Strong Buy
- Analyst Count
- FUFUW 0
- CMMB 2
- Target Price
- FUFUW N/A
- CMMB $9.00
- AVG Volume (30 Days)
- FUFUW 5.6K
- CMMB 863.6K
- Earning Date
- FUFUW 04-11-2025
- CMMB 03-03-2025
- Dividend Yield
- FUFUW N/A
- CMMB N/A
- EPS Growth
- FUFUW 1042.93
- CMMB N/A
- EPS
- FUFUW 0.23
- CMMB N/A
- Revenue
- FUFUW $452,743,012.00
- CMMB N/A
- Revenue This Year
- FUFUW N/A
- CMMB N/A
- Revenue Next Year
- FUFUW N/A
- CMMB N/A
- P/E Ratio
- FUFUW $22.02
- CMMB N/A
- Revenue Growth
- FUFUW 78.43
- CMMB N/A
- 52 Week Low
- FUFUW $0.46
- CMMB $0.58
- 52 Week High
- FUFUW $0.54
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- FUFUW N/A
- CMMB 38.56
- Support Level
- FUFUW N/A
- CMMB $1.21
- Resistance Level
- FUFUW N/A
- CMMB $1.54
- Average True Range (ATR)
- FUFUW 0.00
- CMMB 0.16
- MACD
- FUFUW 0.00
- CMMB -0.01
- Stochastic Oscillator
- FUFUW 0.00
- CMMB 32.73
About FUFUW BitFuFu Inc.
BitFuFu Inc is a digital asset mining and cloud-mining service provider that fosters a secure, compliant, and transparent blockchain infrastructure. It provides stable and intelligent digital asset mining solutions, including one-stop cloud-mining services and miner hosting services to institutional customers and individual digital assets.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.